Catheter Precision, Inc. Announces Annual Meeting of Stockholders on July 3, 2024

TL;DR

<b>Catheter Precision, Inc. will hold its annual meeting of stockholders virtually on July 3, 2024, to elect directors and vote on a proposed reverse stock split and reduction in authorized shares.</b>

AI Summary

Catheter Precision, Inc. (VTAK) filed a Proxy Statement (DEF 14A) with the SEC on May 16, 2024. Catheter Precision, Inc. will hold its annual meeting of stockholders virtually on July 3, 2024, at 9:00 a.m. Pacific time. Stockholders must register by 8:59 p.m. Pacific time on July 2, 2024, to attend the virtual meeting. The meeting agenda includes the election of two Class III directors. Stockholders will vote on an amendment to reduce authorized capital stock, contingent on a reverse stock split. The proposed reduction in authorized shares ranges from 310 million to 40 million (if reverse split approved) or 110 million (if not approved).

Why It Matters

For investors and stakeholders tracking Catheter Precision, Inc., this filing contains several important signals. The virtual format and registration deadline require active participation from stockholders to ensure their vote is counted. The proposed reverse stock split and reduction in authorized shares could significantly alter the company's share structure and potentially impact its stock price and market perception.

Risk Assessment

Risk Level: low — Catheter Precision, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate immediate high risk.

Analyst Insight

Stockholders should review the proposals regarding the reverse stock split and authorized share reduction carefully before voting, as these actions will impact the company's capital structure.

Key Numbers

• July 3, 2024 — Annual Meeting Date (Catheter Precision, Inc. Annual Meeting)
• 9:00 a.m. Pacific time — Meeting Time (Virtual Annual Meeting)
• July 2, 2024 — Registration Deadline (To attend the virtual meeting)
• 310 million — Current Authorized Shares (Total authorized capital stock)
• 40 million — Proposed Authorized Shares (with reverse split) (Reduced authorized capital stock)
• 110 million — Proposed Authorized Shares (without reverse split) (Reduced authorized capital stock)

Key Players & Entities

• Catheter Precision, Inc. (company) — Registrant
• July 3, 2024 (date) — Annual Meeting date
• July 2, 2024 (date) — Registration Deadline
• 310 million shares (dollar_amount) — Current authorized capital stock
• 40 million shares (dollar_amount) — Proposed authorized capital stock if reverse split approved
• 110 million shares (dollar_amount) — Proposed authorized capital stock if reverse split not approved

FAQ

Risk Factors

• Reverse Stock Split and Authorized Share Reduction [medium — financial]: The company proposes a reverse stock split and a significant reduction in authorized shares, which could impact stock price and investor perception.

Key Dates

• 2024-07-03: Annual Meeting of Stockholders — Election of directors and vote on stock split proposals.
• 2024-07-02: Registration Deadline — Last day to register for the virtual annual meeting.

Glossary

Reverse Stock Split

A stock split in which the number of outstanding shares is decreased. (Aims to increase the per-share market price of common stock, potentially making it more attractive to investors.)

Authorized Capital Stock

The maximum number of shares a corporation is authorized to issue. (Reducing authorized shares can streamline the company's capital structure and potentially avoid future dilution.)

Filing Documents

• rmed_def14a.htm (DEF 14A) — 814KB
• rmed_def14aimg10.jpg (GRAPHIC) — 3KB
• rmed_def14aimg3.jpg (GRAPHIC) — 17KB
• rmed_def14aimg4.jpg (GRAPHIC) — 14KB
• rmed_def14aimg5.jpg (GRAPHIC) — 8KB
• rmed_def14aimg6.jpg (GRAPHIC) — 6KB
• rmed_def14aimg7.jpg (GRAPHIC) — 9KB
• rmed_def14aimg8.jpg (GRAPHIC) — 3KB
• rmed_def14aimg9.jpg (GRAPHIC) — 3KB
• 0001654954-24-006536.txt (&nbsp;) — 904KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 55 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 61

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 64 OTHER MATTERS 66 Delinquent Section 16(a) Reports 66 Fiscal Year 2023 Annual Report 66 Company Website 66 Availability of Bylaws 66 PROPOSALS OF STOCKHOLDERS FOR 2025 ANNUAL MEETING 67 v Table of Contents CATHETER PRECISION, INC. 1670 Highway 160 West Suite 205 Fort Mill, SC 29708 PROXY STATEMENT For the 2024 Annual Meeting of Stockholders To be held on July 3, 2024 The information provided in the "Questions and Answers" format below is for your convenience only and is merely a summary of the information contained in this proxy statement. You should read the entire proxy statement carefully. QUESTIONS AND ANSWERS ABOUT US, THE PROXY MATERIALS AND THE ANNUAL MEETING How did Ra Medical Systems, Inc. become Catheter Precision, Inc.? On January 9, 2023, the Company merged with Catheter Precision, Inc., or "Old Catheter," a privately-held Delaware corporation (the "Merger"), and the business of Old Catheter became a wholly owned subsidiary of the Company, which today is our only operating subsidiary. Following the Merger, we discontinued the Company's legacy lines of business and shifted the focus of our operations to Old Catheter's product lines. Accordingly, our current activities primarily relate to Old Catheter's historical business, which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology, or "EP." As a result, the Company, known at that time as Ra Medical Systems, Inc., changed its name to Catheter Precision, Inc. in August 2023. Where can I access the proxy materials? Pursuant to the rules of the U.S. Securities and Exchange Commission, we have provided access to our proxy materials over the Internet. Accordingly, a Notice of Internet Availability of Proxy Materials (the "Internet Notice") has been sent to our stockholders of record and beneficial owners as of the record

View Full Filing

View this DEF 14A filing on SEC EDGAR